Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Trial of Adalimumab in Progressive Sarcoidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00311246
Recruitment Status : Terminated (Difficulty in recruiting subjects)
First Posted : April 5, 2006
Results First Posted : August 14, 2020
Last Update Posted : August 25, 2020
Information provided by (Responsible Party):
University of Chicago

Brief Summary:

Sarcoidosis is a rare disease that can affect any organ in the body. It is characterized by the buildup of immune-system (fights off infection in the body) cells in organs. These cells form small groups called granulomas, which lead to inflammation of the surrounding tissue. Sarcoidosis most commonly affects the lung and the lymph nodes (part of the immune system). The signs usually include shortness of breath, fever, dry cough, and chest pain. Other signs in many patients can include redness and painful lumps on the skin, reduced eyesight, joint pain, and rarely, nervous system damage. Sarcoidosis commonly affects young and middle-aged adults.

There are no approved therapies for the treatment of sarcoidosis. Corticosteroid (steroid hormone) therapy is considered the standard treatment. Only limited benefit has been shown when using corticosteroid therapy to ease lung symptoms or improve lung function in patients with sarcoidosis. Also, the effects of other therapies (for example: methotrexate, cyclophosphamide, anti-malarial drugs, thalidomide) and other immunosuppressants (drugs that suppress a body's natural defense system [immune system]) which have been used in a small number of patients are not well known and can cause long term problems.

The drug used in this study is called adalimumab. Adalimumab is FDA (Food and Drug Administration) approved for patients with moderately to severely active rheumatoid arthritis. However, adalimumab is not approved for the treatment of sarcoidosis. Adalimumab is experimental in this study. The purpose of this study is to evaluate the safety and effectiveness of adalimumab in the treatment of patients with sarcoidosis with pulmonary (lung) involvement who show symptoms of the disease even though they are currently being treated with medication.

Condition or disease Intervention/treatment Phase
Sarcoidosis Drug: Adalimumab Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Open-Label Trial of Adalimumab in Progressive Sarcoidosis
Study Start Date : April 2006
Actual Primary Completion Date : May 2008
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sarcoidosis
Drug Information available for: Adalimumab

Arm Intervention/treatment
Experimental: An open-label
Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52
Drug: Adalimumab
Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
Other Name: Humira

Primary Outcome Measures :
  1. Change in FVC From Screening to Week 24 [ Time Frame: 24 Weeks ]
    The forced vital capacity (FVC) measurement shows the amount of air a person can forcefully and quickly exhale after taking a deep breath. Improvement in FVC, if significant, means better breathing and lung function. The change in FVC done at screening and at week 24 were compared to notice if there were any changes.

Secondary Outcome Measures :
  1. Change in Distance Walked During 6 Minute Walk Test at Screening and 24 Weeks [ Time Frame: 24 weeks ]
    This is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes

  2. A Change in the Borg Dyspnea Score Before/After the 6 Minute Walk at Screening (S) and at 24 Weeks (W). [ Time Frame: 24 weeks ]
    This scale was used to measure a patients breathlessness before/after the 6 Minute Walk. This score was used at Screening (S) and at 24 weeks (W). The borg scale ranges from zero to 10 with zero being no breathlessness at all and 10 being maximal breathlessness. A change between screening and week 24 is reported.

  3. Physicians Global Assessment of Disease Activity. [ Time Frame: 24 weeks ]
    This assessment to determine the level of disease activity. Scores range from 0 (no pulmonary manifestations of sarcoidosis) to 100 (worsening of pulmonary symptoms) on a visual analog scale.

  4. Patient's Global Assessment of Disease Activity. [ Time Frame: 24 weeks ]
    This is the patients measurement of disease activity. Scores range from 0 (no pulmonary manifestations of sarcoidosis) to 100 (worsening of pulmonary symptoms) on a visual analog scale.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women > 18 years of age.
  • Sarcoidosis diagnosed at least 1 year prior to screening.
  • Histologically proven sarcoidosis prior to screening.
  • Have a diagnosis of sarcoidosis with evidence of parenchymal disease on chest radiograph (Stage II or III) or Stage I disease by chest radiographs and evidence of abnormal PFT as below or normal chest radiograph; or abnormal PFT, with abnormal chest computed tomography (CT) and evidence of sarcoid lung involvement by histology. Subjects with concurrent extrapulmonary sarcoidosis, particularly skin and eye involvement, are encouraged to be enrolled.
  • Have forced vital capacity (FVC) > 40 and < 80% of predicted.
  • Have an American Thoracic Society (ATS) dyspnea score of > Grade 1.
  • Have been receiving pre-study treatment that includes at least 10 mg/day prednisone (or equivalent dose of corticosteroid) as a single agent, or 1 or more immunosuppressant (e.g., methotrexate, azathioprine, cyclophosphamide, chloroquine, leflunomide, hydroxychloroquine, mycophenolate mofetil, cyclosporine, tacrolimus, corticosteroids) for at least the 3-month period immediately prior to screening. Subjects must be on a stable dose of these medications for > 4 weeks before starting the study medication.
  • Adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) must be used for the duration of the study and such precautions should be continued for 6 months after receiving the last study agent injection.
  • Are considered eligible based on TB screening

Exclusion Criteria:

  • Have used any investigational drug within 1 month prior to screening.
  • Have received previous administration of a treatment with any other therapeutic agent targeted at reducing tumor necrosis factor [TNF] (e.g., pentoxifylline, thalidomide, etanercept, infliximab) within 3 months prior to screening.
  • Have received previous administration of adalimumab.
  • Have received any live virus or bacterial vaccinations within the 3 months before the first dose of the study agent or are expected to receive any live virus or bacterial vaccinations during the trial or up to 3 months after the last dose of the study agent.
  • Have had any previous adverse reactions or allergic reactions (e.g., anaphylaxis) associated with the administration of monoclonal antibodies.
  • Have New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF).
  • Have a history of severe right-sided heart failure or cor pulmonale.
  • Have had serious infections within 2 months of screening. Less serious infections (such as acute upper respiratory tract infection [colds] or a simple urinary tract infection) need not be considered as exclusion at the discretion of the investigator.
  • Are considered ineligible according to the United States of America (USA)-specific TB screening.
  • Have or have had an opportunistic infection (e.g., herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis and aspergilloma, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening.
  • Have a known infection with human immunodeficiency virus (HIV).
  • Have current signs and symptoms of systemic lupus erythematosus, or severe, progressive, or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic, or cerebral diseases (with the exception of sarcoidosis).
  • Presence of a transplanted organ (with the exception of a corneal transplant) > 3 months prior to screening.
  • Have any known malignancy or history of malignancy within 5 years prior to screening.
  • Have a history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease.
  • Are pregnant, nursing, or planning pregnancy (both men and women) during the trial or within the 6-month period thereafter.
  • Have had a known substance abuse or dependency, drug or alcohol within 3 years of screening.
  • Have poor tolerability of subcutaneous injection or lack of adequate venous access for required blood sampling.
  • Have a known history of demyelinating disease such as multiple sclerosis or optic neuritis.
  • Presence of a non-sarcoidosis condition affecting survival.
  • Have mental health problems interfering with participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00311246

Layout table for location information
United States, Illinois
The University of Chicago
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
Layout table for investigator information
Principal Investigator: Nadera J. Sweiss, M.D. The University of Chicago Hospitals
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Chicago Identifier: NCT00311246    
Other Study ID Numbers: University of Chicago #14093A
First Posted: April 5, 2006    Key Record Dates
Results First Posted: August 14, 2020
Last Update Posted: August 25, 2020
Last Verified: March 2020
Keywords provided by University of Chicago:
Tumor Necrosis Factor Inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoproliferative Disorders
Lymphatic Diseases
Anti-Inflammatory Agents
Antirheumatic Agents